AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04516538 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cycloergometer body weight-based quadriceps intermittent fatigue test (BW-QIF Test)
Description: The BW-QIF test is an interval incremental contraction test including blocks of discontinuous 100-s effort. Neuromuscular evaluation of the knee extensors between blocks (duration 25 s) includes one maximal voluntary contraction, one contraction at the 60% of the actual maximal force and at the 80% of the actual maximal force. During each contraction, transcranial magnetic stimulation over the motor cortex will be delivered to assess corticospinal voluntary activation (central fatigue). Single-twitch electrical stimulations will be delivered on the femoral nerve during the maximal voluntary contraction and at rest to evaluate peripheral fatigue.~The BW-QIF test blocks on the cycloergometer consist in 100 s of cycling at 60 Revolution Per Minute (RPM).
Study NCT04516538 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Isometric BW-QIF Test (Body weight-based quadriceps intermittent fatigue test)
Description: The BW-QIF test is an interval incremental contraction test including blocks of discontinuous 100-s effort. Neuromuscular evaluation of the knee extensors between blocks (duration 25 s) includes one maximal voluntary contraction, one contraction at the 60% of the actual maximal force and at the 80% of the actual maximal force. During each contraction, transcranial magnetic stimulation over the motor cortex will be delivered to assess corticospinal voluntary activation (central fatigue). Single-twitch electrical stimulations will be delivered on the femoral nerve during the maximal voluntary contraction and at rest to evaluate peripheral fatigue.~The isometric BW-QIF test blocks consist in 10 contractions (5-s contraction / 5-s rest).
Study NCT05994300 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Moderately hypofractionated adaptive radiotherapy (ART)+ High-dose rate (HDR) Brachytherapy
Description: Experimental: 43.35Gy/17F external beam radiotherapy (EBRT) with adaptive radiotherapy (ART) + HDR-Brachytherapy~Drug: Concurrent Chemotherapy~Weekly cisplatin 40 mg/m2
Study NCT06462625 — intervention group
Intervention type: OTHER
Intervention: High tibial osteotomy
Description: Correction of lower limb malalignement with tibial bone wedge insertion/removal
Study NCT04855695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Each study drug is given according to a different schedule:~Acalabrutinib: Oral, dosage per protocol, start cycle 1 and beyond according to schedule outlined in protocol
Study NCT04855695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax: oral. daily, dosage per protocol, start cycle 3 and beyond according to schedule outlined in protocol
Study NCT04855695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab: intravenous infusion, dosage per protocol, drug during cycles 2 and beyond according to schedule outlined in protocol
Study NCT05068232 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ablative Radiation
Description: Ablative radiation therapy is a highly focused radiation treatment that gives an intense dose of radiation concentrated on a tumor or very specific area of the body, while limiting the radiation that affects surrounding organs.
Study NCT05068232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is an immunotherapy drug -- a drug used to help boost your immune response to fight cancer.
Study NCT05068232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide is a chemotherapy drug approved for different kinds of cancer, including small cell lung cancer.
Study NCT05068232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is a chemotherapy drug approved for different kinds of cancer, including small cell lung cancer.
Study NCT05903807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPi-46
Description: Ovarian cancer patients undergo 68Ga-FAPI-46 at primary staging and at restaging
Study NCT06478693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-303
Description: MT-303
Study NCT05437055 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical Thrombectomy (Penumbra System with Thunderbolt)
Description: Subject will receive Penumbra System with Thunderbolt
Study NCT05588960 — intervention group
Intervention type: DEVICE
Intervention: Near-infrared spectroscopy monitoring (Masimo O3 Regional Oximeter with Neonatal Sensor)
Description: Masimo O3 neonatal sensor will be applied:~* At least 30 minutes before a period of skin-to-skin care with a caregiver commences (baseline condition).~* Throughout the period of skin-to-skin care, which should continue for a minimum of 1 hour.~* For at least 1 hour after the participant is returned to their incubator (post-intervention condition).~The protocol accounts for a 30 minute washout period between each study epoch. Therefore, at least 30 minutes of study data will be collected for each epoch.
Study NCT05588960 — intervention group
Intervention type: DEVICE
Intervention: Near-infrared spectroscopy monitoring (Masimo O3 Regional Oximeter with Neonatal Sensor)
Description: Masimo O3 neonatal sensor will be applied:~▪ For 24 hours once the participant reaches 36 weeks corrected gestational age.
Study NCT04433741 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oxytocin
Description: Oxytocin administered intravenously
Study NCT04433741 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo administered intravenously
Study NCT06277700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chiropractic Manipulation (HVLA - high velocity low amplitude)
Description: Participants in the groups receiving DNS will be asked to hold the lower leg in the side lying position with the lower leg in the extended position and to clamp the upper leg to the lower leg with hip and knee flexion. During the application, the HLVA technique will be applied once by positioning the hypothenar part of the physiotherapist's hand on the transverse process of the lumbar vertebra where tenderness is felt by palpation and vertebral subluxation is thought to be present.
Study NCT06277700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic Neuromuscular Stabilization
Description: Participants in the groups receiving DNS exercise therapy will be given individualized exercises under the supervision of a physiotherapist. First, the participants were taught posterior diaphragm activation in the supine position and the ability to direct the intraabdominal pressure caudally, while preventing the cranial movement of the thorax, so that the chest and pelvis are in a neutral position and the thoracic diaphragm and pelvis are aligned in parallel. Participants will then be taught the ability to perform a chin tuck without disturbing the alignment of the rib cage. In this way, the cervical diaphragm, thoracic diaphragm and pelvic diaphragm will be aligned in parallel. Our aim in this alignment will be to activate the deep stabilizers as a reflex response to intra-abdominal pressure change with the correct diaphragm movement pattern. Participants will be asked to focus on and maintain this alignment throughout the entire DNS exercise pattern.
Study NCT05949788 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Retrospect study, no direct intervention
Study NCT06000059 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Radio Drama
Description: An hour long radio drama adapted from from a previous community-led theater intervention
Study NCT05908695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GV-971
Description: Administered PO
Study NCT04713969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40mg
Description: Pantoprazole 40mg twice daily
Study NCT05908695 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered PO
Study NCT06521554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVL-330
Description: Oral Tablet of NVL-330
Study NCT06217822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 225Ac-PSMA-Trillium (BAY3563254)
Description: Intravenous slow injection on Day 1 of a 6 week treatment cycle.
Study NCT05589194 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nursing Practices Based on Kolcaba's Comfort Theory
Description: Nursing interventions planned to be carried out within the scope of the research will be based on Comfort Theory. Nursing interventions will be planned according to the needs in the physical comfort (diet practice, providing effective and correct pelvic floor muscle contraction, repetitive and regular yoga practice training), psychospiritual comfort (appreciation and encouragement, self-confidence, expressing the feeling of embarrassment, expressing fear, confidence, repetitive and regular practice of yoga practice, meditation), sociocultural comfort (to be informed, to develop effective interpersonal communication, to interact with other women with SUI) and environmental comfort (Informing about making the necessary arrangements to prevent possible situations such as sleep disruption and falling, bad smell, etc. and performing nursing practices by respecting privacy). The yoga practice will carry out with the participation of 60-minute group yoga classes twice a week for 6 weeks.
Study NCT05967364 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wingman-Connect
Description: Training occurs in three 2-hr blocks over several days in class groups. Targeted Skills focus on protective factors (Four Cores) supportive of mental health, theoretically linked to reduced suicide risk, and essential to an Airmen's job success: (1) Healthy relationships and accountability spanning USAF and family/intimate relationships (Kinship); (2) Meaning and value in work and life (Purpose), (3) Informal and formal help-seeking (Guidance); and (4) Activities that give strength and balance emotions (Balance). Activities progress from individual to group skill-building activities. Kinship modules at operational base (FTAC) expand focus on growing and sustaining relationships with intimate partners, friends, and family; and Guidance more on senior mentors at work. To extend training impact, facilitators implement activities once per quarter that bring concepts into base activities. Six months of text messages (1-2 per week) to reinforce and extend program concepts and skills.
Study NCT05967364 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Management
Description: Stress management training (also done in class groups) reviews the basics of the hypothalamic-pituitary-adrenal axis stress-response system; common experiences of stress (physiological, cognitive, emotional); the impact of chronic stress on the brain and other domains of health; how exercise reduces harmful effects of stress; and relaxation techniques that have been shown to reduce stress and adverse effects of stress on health. Additional modules review the physiological stress response and effects of stress on health; introduces how cognition influences stress responses; common cognitive distortions/attributions are reviewed that affect stress including strategies to strengthen protective cognitive responses. Six months of text messages (1-2 per week) to reinforce and extend program concepts and skills.
Study NCT05334784 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Impella ECP
Description: Subjects will receive the Impella ECP prior to high-risk percutaneous intervention. Device escalation or early termination of the study will be allowed for subjects as deemed necessary by the treating physician. Subjects will be followed until 30-days post-intervention.
Study NCT04629950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimegepant
Description: Active Agent
Study NCT04629950 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study NCT06181760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenretinide
Description: Ascending single doses of oral fenretinide
Study NCT06181760 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral dose of matching placebo capsules
Study NCT05726981 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fine needle aspiration biopsy (FNAB)
Description: Thyroid FNAB is a minimally invasive procedure performed routinely by an experienced sonographer.~It is a safe and brief procedure, performed with a 27G or 25G (very fine) needle (3 needles, i.e. 1 needle per pass)
Study NCT05456373 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClearEdge device
Description: ClearEdge tissue imaging device uses a new technology to detect tissue abnormalities at the surgical margins of a surgically excised breast tissue specimen. Adding the use of the imaging device has the potential to assist the surgeon in identifying DCIS or invasive cancer involved margins of the excised specimen.
Study NCT06591026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated Text Messaging (ATM)
Description: Automated text messages are sent daily for 4 weeks.
Study NCT04805736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab 200 mg was given a few days after microwave ablation
Study NCT06618014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab was given 240 mg intravenously on day 1 of each 21-day cycle for 6 cycles.
Study NCT06618014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel was administered at a dose of 75 mg/m2 on day 1 of each 21-day cycle for 6 cycles.
Study NCT06618014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 4 on day 1 of each 21-day cycle for 6 cycles.
Study NCT05578781 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Music Therapy is a music session with a live therapist and has been shown to reduce pain and anxiety. If effective the music medicine in this RCT will be used help design a full R01 study
Study NCT05578781 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Medicine
Description: Music Medicine is an audio recorded music therapy session that will be played for the participant. This will be the same music session that will be played live in the music therapy session.
Study NCT05578781 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control group
Description: Control group will listen to an audio recording of text being spoken by the board certified music therapist
Study NCT05578781 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Control group will listen to an audio recording of text being spoken by the board certified music therapist
Study NCT06155838 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Adolescent Skills for Emotions (EASE)
Description: Weekly Schedule for Teen's and their parents Sessions:~Over the course of 7 sessions, with one session per week lasting 90 minutes, the following core components will be covered:~Week 1: Exploring My Feelings~Week 2: Learning to Calm~Week 3 \& 4: Learning CBT- Restructuring My Thinking, Changing Feelings and My Actions \& Managing My Emotions and Issues~Week 5 \& 6: Fostering Independent Problem-Solving Skills and Seeking Help~Week 7: Relapse Prevention~2.0 For parents/ guardians~Week 3 Psychoeducation (to develop skills to be able to identify, listen, better respond and provide comfort to teens when they are overwhelmed by anxiety and depression).~Week 4 Positive parenting strategies~Week 5 Parents/ guardians Self-care
Study NCT05370391 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Behavioral Intervention for Tics (CBIT)
Description: The CBIT (or CBIT-JR) intervention consists of a minimum of 6 sessions of 50-minutes each week in an individual or group setting.
Study NCT06625567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animated video
Description: Patients will watch an educational video describing the procedure before hysteroscopy without anesthesia
Study NCT05832437 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BREATHE-Peds Intervention
Description: BREATHE-Peds utilizes Primary Care Providers (PCPs) to deliver a 4-step script that was created by and tailored to Black adults' asthma and inhaled corticosteroid beliefs, as well as their Asthma Control Questionnaire (ACQ) score, measured just prior to the medical visit. Step 1: Raise the subject (1½ minute). Step 2: Provide feedback (1½ minutes). Step 3: Enhance engagement (3 minutes). Step 4: Shared decision-making (3 minutes).
Study NCT06646276 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986489 (BMS-986012+Nivolumab)
Description: Specified dose on specified days
Study NCT06646276 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Specified dose on specified days
Study NCT06646276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Specified dose on specified days
Study NCT06646276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Specified dose on specified days
Study NCT06646276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Specified dose on specified days
Study NCT06646276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Specified dose on specified days
Study NCT05216432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLY-2608
Description: RLY-2608 is a mutant-selective, oral PI3Kα inhibitor.
Study NCT05216432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg fulvestrant is administered intramuscularly on Cycle 1 Day 1, Day 15, and Day 1 of each subsequent cycle (where a cycle is 28 days).
Study NCT05832437 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Intervention
Description: The control intervention will be a 9-minute scripted discussion tailored to living a health lifestyle. Step 1: Review of BMI, current diet and exercise (3 minutes). Step 2: Diet/exercise counseling (3 minutes). Step 3: Plan for goal attainment (3 minutes).
Study NCT06633055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JH013 injection
Description: JH013 injection is a BAFF-R inhibitor monoclonal antibody
Study NCT06633055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: JH013 injections placebo
Study NCT05216432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib 125mg
Description: 125mg palbociclib is taken orally once daily for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
Study NCT05216432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib 400mg
Description: 400mg ribociclib is taken orally once daily for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
Study NCT05216432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib 600mg
Description: 600mg ribociclib is taken orally once daily for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
Study NCT05216432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07220060 100mg
Description: is taken orally twice daily at the same time with RLY-2608 during each 28-day cycle.
Study NCT05216432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07220060 300 mg
Description: is taken orally twice daily at the same time with RLY-2608 during each 28-day cycle.
Study NCT06704204 — intervention group
Intervention type: DRUG
Intervention: The first FDA-approved LAI ART regimen includes an integrase inhibitor, cabotegravir (CAB), and a non-nucleoside reverse transcriptase inhibitor, rilpivirine (RPV) combined 4 wks
Description: To date, there have been no studies looking at the use of LAI ART among justice involved PWH, yet a significant opportunity exists to improve HIV treatment outcomes in this high risk population.30
Study NCT05974618 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: A standardised transvaginal (supplemented with transabdominal if transvaginal is not sufficient) examination is performed. When a colour Doppler ultrasound examination is performed, the pulse repetition frequency should be 0.3-0.6 KHz. The colour Doppler gain should be increased until colour Doppler artefacts appear and then lowered until just below the reappearance of colour Doppler artefacts. Ultrasound frequency and priority (grey scale or colour/Power Doppler) must also be optimised when using colour/power Doppler. Doppler ultrasound should be used with all masses included, irrespective of gestational age.
Study NCT06761521 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Peri-Implantitis and Peri-implant mucositis
Description: peri-implant mucositis, peri-implantitis
Study NCT06760637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07220060
Description: CDK4 inhibitor
Study NCT06760637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: endocrine therapy
Study NCT04944953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A Injection [Botox]
Description: Single administration, Day 0, 20 units
Study NCT04944953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A injection [HG-102]
Description: Single administration, Day 0, 20 units
Study NCT05324553 — intervention group
Intervention type: PROCEDURE
Intervention: Tissue Collection
Description: Research tissue specimen will be obtained during the patient's clinical biopsy or clinical tumor resection, if feasible.